Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
Sebastian BeerJonas BabelNeef MartinValentin BlankJohannes WiegandThomas KarlasPublished in: PloS one (2023)
MAFLD is a frequent comorbidity in patients at CAD risk, but advanced liver disease has a low prevalence in patients undergoing elective coronary angiography. Therefore, a routine VCTE-based screening for FLD cannot be recommended in cardiac patients. The association of indicators of steatohepatitis with advanced CAD points to inflammatory processes as a conjoint mechanism of both diseases.
Keyphrases
- coronary artery disease
- patients undergoing
- end stage renal disease
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- cardiovascular events
- coronary artery bypass grafting
- oxidative stress
- risk factors
- peritoneal dialysis
- left ventricular
- clinical practice
- type diabetes
- cardiovascular disease
- acute coronary syndrome
- atrial fibrillation